Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.
This study assessed (1) T-cell responses following vaccination of HIV-1 negative volunteers with HIV-1LAI recombinant gp160 (rgp160) vaccine, and (2) effects of vaccine injection schedule and MHC HLA type on those responses. In one trial, volunteers received rgp160 in two accelerated schedules (Groups 1 and 2). In the other trial, volunteers received rgp160 vaccine at 0, 1, 6, and 12 months and some received vaccine at 18 months (Groups 3 and 4). Peripheral blood mononuclear cells (PBMC) from vaccinees in Groups 3 and 4 were stimulated by more peptides representing envelope glycoprotein T-cell epitopes than Groups 1 and 2 (p = 0.01). Transient anti-envelope glycoprotein CTL activity was more frequently detectable in Groups 1 and 2 (p = 0.03). MHC HLA-Cw7, DR1 and DQw1 alleles appeared to be associated with PBMC responses to envelope glycoprotein.
Gorse
G J
GJ
Division of Infectious Diseases, St. Louis University Health Sciences Center, MO 63110-0250, USA.
Patel
G B
GB
Newman
F K
FK
Mandava
M
M
Belshe
R B
RB
D016915:AIDS Vaccines / Q000008:administration & dosage*; D000595:Amino Acid Sequence; D000818:Animals; D002417:Cattle; D002455:Cell Division / Q000276:immunology; D003601:Cytotoxicity Tests, Immunologic; D015686:Gene Products, env / Q000276:immunology*; D019302:HIV Envelope Protein gp160; D015497:HIV-1 / Q000276:immunology*; D006649:Histocompatibility Antigens / Q000276:immunology*; D007111:Immunity, Cellular; D007115:Immunization Schedule; D008214:Lymphocytes / Q000166:cytology; D008297:Male; D008969:Molecular Sequence Data; D010455:Peptides / Q000276:immunology; D011498:Protein Precursors / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage*
D016915:AIDS Vaccines; D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D006649:Histocompatibility Antigens; D010455:Peptides; D011498:Protein Precursors; D014614:Vaccines, Synthetic